ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases ...Middle East

PR Newswire - News
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases

- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to effectively deliver molecules across the blood-brain barrier - ABL Bio to receive up to £77 million in...

    Read More Details
    Finally We wish PressBee provided you with enough information of ( ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases )

    Also on site :